Inflammation Research

, Volume 63, Issue 2, pp 105–107 | Cite as

Inflammaging: should this term be suitable for age related macular degeneration too?

  • Carla Enrica Gallenga
  • Francesco Parmeggiani
  • Ciro Costagliola
  • Adolfo Sebastiani
  • Pier Enrico Gallenga



Inflammaging is a phenomenon triggered by the conjunction of chronic repetitive and subclinical inflammation from external aggressors and internal inflammatory mechanisms due to the progressive degradation of systems such as the mitochondrial function. Age-related macular degeneration is the leading cause of blindness and visual impairment in patients older than 60 years in developed countries.


Remarkable correlations have been documented between common or rare immunological/inflammatory gene polymorphisms and AMD, unequivocally indicating the involvement of inflammation and immune-mediated processes (complement activation) in the pathogenesis of this disease.


Altogether these factors also drive this pathologic condition under the general heading of “Inflammaging”.


Inflammaging Age related macular degeneration Cytokines Complement 


  1. 1.
    Franceschi C, Capri M, Monti D, Giunta S, Olivieri F, Sevini F, Panourgia MP, Invidia L, Celani L, Scurti M, Cevenini E, Castellani GC, Salvioli S. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev. 2007;128:92–105.PubMedCrossRefGoogle Scholar
  2. 2.
    Lio D, Scola L, Crivello A, Colonna-Romano G, Candore G, Bonafe M, Cavallone L, Franceschi C, Caruso C. Gender-specific association between -1082 IL-10 promoter polymorphism and longevity. Genes Immun. 2002;3:30–3.PubMedCrossRefGoogle Scholar
  3. 3.
    Franceschi C, Bonafe M, Valensin S, Olivieri F, De Luca M, Ottaviani E, De Benedictis G. Inflammaging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000;908:244–54.PubMedCrossRefGoogle Scholar
  4. 4.
    Giunta S. Is inflammaging an auto[innate]immunity subclinical syndrome? Immun Ageing. 2006;16:3–12.Google Scholar
  5. 5.
    Goto M. Inflammaging (inflammation + aging): a driving force for human aging based on an evolutionarily antagonistic pleiotropy theory? Biosci Trends. 2008;2:218–30.PubMedGoogle Scholar
  6. 6.
    Mc Dade TW. Early environments and the ecology of inflammation. PNAS. 2012;109:17281–8.CrossRefGoogle Scholar
  7. 7.
    Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in atherosclerosis: transition from theory to practice. Circ J. 2010;74:213–20.PubMedCrossRefGoogle Scholar
  8. 8.
    Paolisso G, Rizzo MR, Mazziotti G, Tagliamonte MR, Gambardella A, Rotondi M, Carella C, Giugliano D, Varricchio M, D’Onofrio F. Advancing age and insulin resistance: role of plasma tumor necrosis factor-alpha. Am J Physiol. 1998;275:E294–9.PubMedGoogle Scholar
  9. 9.
    Kanterman J, Sade-Feldman M, Baniyash M. New insights into chronic inflammation-induced immunosuppression. Semin Cancer Biol. 2012;22:307–18.PubMedCrossRefGoogle Scholar
  10. 10.
    Klein R, Peto T, Bird A, et al. The epidemiology of age-related macular degeneration. Am J Ophthalmol. 2004;137:486–95.PubMedCrossRefGoogle Scholar
  11. 11.
    Parmeggiani F, Romano MR, Costagliola C, Semeraro F, Incorvaia C, D’Angelo S, Perri P, De Palma P, De Nadai K, Sebastiani A. Mechanism of inflammation in age-related macular degeneration. Mediators Inflamm. 2012;2012:546786. doi: 10.1155/2012/546786.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Lin T, Walker GB, Kurji K, Fang E, Law G, Prasad SS, Kojic L, Cao S, White V, Cui JZ, Matsubara JA. Parainflammation associated with advanced glycation endproduct stimulation of RPE in vitro: Implications for age-related degenerative diseases of the eye. Cytokine. 2013;62:369–81.PubMedCrossRefGoogle Scholar
  13. 13.
    Russo A, Costagliola C, Delcassi L, Romano MR, Semeraro F. A randomised controlled trial of ranibizumab with and without ketorolac eyedrops for exudative age-related macular degeneration. Br J Ophthalmol. 2013;97:1273–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Chedraui P, Pérez-López FR. Nutrition and health during mid-life: searching for solutions and meeting challenges for the aging population. Climacteric. 2013;16 Suppl:85–95.CrossRefGoogle Scholar
  15. 15.
    Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. 2013;309:2005–15.CrossRefGoogle Scholar
  16. 16.
    McGeer PL, McGeer EG. Inflammation and the degenerative diseases of aging. Ann N Y Acad Sci. 2004;1035:104–16.PubMedCrossRefGoogle Scholar
  17. 17.
    Prasad S, Sung B, Aggarwal BB. Age-associated chronic diseases require age-old medicine: role of chronic inflammation. Prev Med. 2012;54 Suppl:S29–37.PubMedCrossRefGoogle Scholar
  18. 18.
    Jenny NS. Inflammation in aging: cause, effect, or both? Discov Med. 2012;13:451–60.PubMedGoogle Scholar

Copyright information

© Springer Basel 2013

Authors and Affiliations

  • Carla Enrica Gallenga
    • 1
  • Francesco Parmeggiani
    • 1
  • Ciro Costagliola
    • 2
  • Adolfo Sebastiani
    • 1
  • Pier Enrico Gallenga
    • 3
  1. 1.Section Ophthalmology, Department of Medical-Surgical Communication and BehaviourUniversity of FerraraFerraraItaly
  2. 2.Department of Medicine and Health Sciences, Chair of OphthalmologyUniversity of MoliseCampobassoItaly
  3. 3.University Eye ClinicG d’Annunzio UniversityChietiItaly

Personalised recommendations